Compare AXR & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXR | KALA |
|---|---|---|
| Founded | 1961 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.1M | 172.0M |
| IPO Year | 2010 | 2017 |
| Metric | AXR | KALA |
|---|---|---|
| Price | $28.24 | $0.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $30.00 | ★ $31.50 |
| AVG Volume (30 Days) | 9.2K | ★ 3.1M |
| Earning Date | 03-12-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.60 | 67.39 |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $12,831,000.00 | N/A |
| Revenue This Year | $10.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.61 | $0.10 |
| 52 Week High | $29.00 | $20.58 |
| Indicator | AXR | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 54.71 | 25.11 |
| Support Level | $20.02 | N/A |
| Resistance Level | $28.57 | $0.24 |
| Average True Range (ATR) | 0.95 | 0.02 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 68.53 | 3.34 |
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.